Printer Friendly

An unexpected cause of elevated prostate specific antigen.

To the Editor: It is known that markedly elevated tumor markers are sensitive for malignancies and may indicate a poor prognosis requiring aggressive therapy. (1) Although rare, it can also be due to nonmalignant conditions. This was highlighted in the case report by Sanchez et al (2) published in the February issue of the Southern Medical Journal. However, a mild elevation can be very nonspecific and associated with many conditions. (1)

A 56-year-old gentleman presented with a long history of intermittent dyspepsia and lower abdominal pain. Two years before his current presentation, he was evaluated in a specialty center abroad. Abdominal ultrasound scan and endoscopic evaluations were normal apart from mild proctitis, a small transverse colon polyp and marked gastritis with intestinal metaplasia. A polypectomy was performed. Histology only showed nonspecific colitis and an adenomatous polyp. He was positive for Helicobacter pylori which was successfully eradicated. He was also treated with a course of antibiotic for presumed infective colitis with some symptom improvement. However, his symptoms remained with intermittent exacerbations. He had no other colonic complaints. A repeat evaluation showed similar findings. A tumor marker panel consisting of prostate specific antigen (PSA), carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA 19-9) and alpha fetoprotein (AFP) showed a mildly elevated PSA and CA 19-9. An ultrasound revealed an enlarged prostate gland. The patient was referred for further evaluation that included a transrectal ultrasound and biopsy. The biopsies showed some abnormal cells but no evidence of malignancy. Because of ongoing abdominal complaints and persistent tumor marker elevation, a repeat colonoscopy was performed to assess the proctitis that was noted earlier. This showed progression to involve the sigmoid colon. Biopsy at this time was consistent with ulcerative colitis with goblet cell depletion, chronic inflammatory infiltration and crypt abscesses. He was started on aminosalicylate therapy with marked symptom improvement. Serial follow up of the tumor markers showed normalization (Fig). Other blood investigations, including erythrocyte sedimentation rate, were all normal.

PSA is very specific for prostate pathology. (1) Unlike PSA, other markers such as CA 19-9, CEA and CA-125 can be elevated in many conditions. (1-5) However, these elevations are usually mild. Apart from the marked gastritis and some abnormal prostate cells, there was no evidence of malignancy or any other pathology that may account for the elevated tumor markers. The normalization after initiating therapy for ulcerative colitis (UC) indicated that the underlying UC was the most likely cause. It is possible that chronic prostate irritation by the proctitis caused the elevated PSA. CA 19-9 elevation is usually due to upper gastrointestinal tract pathology, particularly the pancreaticoiliary system. Again, the mild elevation in our patient is likely to be due to the ulcerative colitis, as after initiating specific treatment, the level decreased.

Despite the nonspecificity of some tumor markers, evaluation needs to be considered, particularly in a patient of advancing age, as the risk of underlying malignancy is higher than in a younger patient. It is well known that a proportion of tumors do not have elevation of tumor markers, even at advanced stages. This case highlights the need to consider inflammatory bowel disease as a cause of elevated PSA.

Vui Heng Chong, MRCP, FAMS

Gastroenterology Unit

Department of Medicine

Raja Isteri Pengiran Anak Saleha Hospital

Bandar Seri Begawan BA 1710

Brunei Darussalam

References

1. Perkins GL, Slater ED, Sanders GK, et al. Serum tumor markers. Am Fam Physician 2003;68:1075-1082.

2. Sanchez M, Gomes H, Marcus EN. Elevated CA 19-9 levels in a patient with Mirizzi syndrome: case report. South Med J 2006;99:160-163.

3. Soardo G, Basan L, Intini S, et al. Elevated serum CA 19-9 in hepatic actinomycosis. Scand J Gastroenterol 2005;40:1372-1373.

4. Obayashi Y, Fujita J, Nishiyama T, et al. Role of carbohydrate antigens sialyl Lewis (a) (CA19-9) in bronchoalveolar lavage in patients with pulmonary fibrosis. Respiration 2000;67:146-152.

5. Ruffini E, Rapellino M, Delsedime L, et al. Pulmonary carcinoembryonic antigen (CEA) production in patients with end-stage lung diseases submitted to lung transplantation. Int J Biol Markers 1997;12:44-45.

Letters to the Editor are welcomed. They may report new clinical or laboratory observations and new developments in medical care or may contain comments on recent contents of the Journal. They will be published, if found suitable, as space permits. Like other material submitted for publication, letters must be typewritten, double-spaced, and must not exceed two typewritten pages in length. No more than five references and one figure or table may be used. See "Information for Authors" for format of references, tables, and figures. Editing, possible abridgment, and acceptance remain the prerogative of the Editors.
 Level (IU/mL)
Timeline (Month /Year) PSA CA 19-9

10/03 11.1 40.3
 3/04 11.3 34.6
 7/04 10.3 37.7
 8/04 11.2 37.9
 3/05 11.9 45.4
 6/05 2.6 1.6
 2/06 1.6 23.6

Note: Table made from line graph.
COPYRIGHT 2006 Southern Medical Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Author:Chong, Vui Heng
Publication:Southern Medical Journal
Article Type:Letter to the editor
Date:Aug 1, 2006
Words:825
Previous Article:Collet-Sicard syndrome: an uncommon manifestation of metastatic prostate cancer.
Next Article:Is eosinophilic gastroenteritis a primary disease or a secondary developing entity due to parasitosis?


Related Articles
Does vasectomy cause prostate cancer?
Foretelling prostate cancer.
Test may better detect prostate cancer.
Detecting cancer risk with a chip. (Biomedicine).
Prostate cancer prevention trial enrolls area men.
Prostate cancer--you can't run away.
GEN-PROBE ACQUIRES DIAGNOSTIC RIGHTS TO PROSTATE CANCER GENE.
Pleural effusion as presentation of metastatic adenocarcinoma of prostate.
CA 19-9: not a magic marker for pancreatic cancer.
Prostate cancer and early BPA exposure.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters